Argos Therapeutics Inc. (ARGS) Downgraded by Zacks Investment Research
Argos Therapeutics Inc. (NASDAQ:ARGS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.
According to Zacks, “Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. “
Several other equities research analysts have also recently weighed in on the company. Piper Jaffray Cos. reiterated an “overweight” rating and set a $11.00 price target on shares of Argos Therapeutics in a research report on Monday, June 20th. FBR & Co decreased their price objective on shares of Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating on the stock in a research report on Thursday, August 11th. Finally, Needham & Company LLC restated a “buy” rating and issued a $11.00 price objective on shares of Argos Therapeutics in a research report on Friday, June 17th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Argos Therapeutics has a consensus rating of “Buy” and an average price target of $11.50.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/argos-therapeutics-inc-args-downgraded-by-zacks-investment-research.html
Argos Therapeutics (NASDAQ:ARGS) traded up 1.03% during midday trading on Tuesday, reaching $4.90. 85,930 shares of the company traded hands. Argos Therapeutics has a one year low of $1.61 and a one year high of $13.97. The stock’s 50 day moving average is $4.87 and its 200 day moving average is $5.92. The company’s market capitalization is $201.86 million.
Argos Therapeutics (NASDAQ:ARGS) last announced its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.05. On average, equities analysts anticipate that Argos Therapeutics will post ($1.56) earnings per share for the current year.
In other Argos Therapeutics news, major shareholder International S. Pharmstandard purchased 75,474 shares of Argos Therapeutics stock in a transaction on Monday, August 22nd. The shares were acquired at an average cost of $4.24 per share, for a total transaction of $320,009.76. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder International S. Pharmstandard purchased 16,977 shares of Argos Therapeutics stock in a transaction on Thursday, September 1st. The shares were acquired at an average price of $4.78 per share, for a total transaction of $81,150.06. The disclosure for this purchase can be found here. Company insiders own 61.64% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Oxford Asset Management acquired a new position in shares of Argos Therapeutics during the second quarter worth approximately $353,000. Geode Capital Management LLC boosted its position in shares of Argos Therapeutics by 7.9% in the first quarter. Geode Capital Management LLC now owns 48,851 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 3,559 shares during the last quarter. California State Teachers Retirement System acquired a new position in shares of Argos Therapeutics during the second quarter worth approximately $137,000. Bank of New York Mellon Corp boosted its position in shares of Argos Therapeutics by 184.5% in the second quarter. Bank of New York Mellon Corp now owns 52,215 shares of the biopharmaceutical company’s stock worth $320,000 after buying an additional 33,862 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. bought a new stake in Argos Therapeutics during the second quarter worth $137,000. Institutional investors and hedge funds own 11.05% of the company’s stock.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.